Wall Street analyst estimates for Moderna, Inc. (MRNA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-1.31 | ||
| 2026-07-31 | $-1.97 | $-2.03 | +3.0% |
| 2026-05-01 | $-3.40 | $-4.45 | +23.6% |
| 2026-02-13 | $-2.11 | $-2.54 | +16.9% |
| 2025-11-06 | $-0.51 | $-1.87 | +72.7% |
| 2025-08-01 | $-2.13 | $-2.99 | +28.8% |
| 2025-05-01 | $-2.52 | $-2.92 | +13.7% |
| 2025-02-14 | $-2.50 | $-2.68 | +6.7% |
Valuation Ratios
| Price / Book | 1.34 |
| EV / EBITDA | -20.01 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $108.4M | $205.8M | $135.1M | $60.2M | $803.4M | $17.74B | $18.88B | $6.85B | $3.20B | $1.94B |
| Cost of Revenue | $15.1M | $20.5M | $24.9M | $31.0M | $39.2M | $2.62B | $5.42B | $4.69B | $1.46B | $868.0M |
| Gross Profit | $93.3M | $185.3M | $110.2M | $29.2M | $764.2M | $15.12B | $13.46B | $2.15B | $1.74B | $1.08B |
| Research & Development | $274.7M | $410.5M | $454.1M | $496.3M | $1.37B | $1.99B | $3.29B | $4.84B | $4.54B | $3.13B |
| Selling, General & Admin | $57.5M | $64.7M | $94.3M | $109.6M | $188.3M | $567.0M | $1.13B | $1.55B | $1.17B | $1.02B |
| Operating Expenses | $317.1M | $454.6M | $94.3M | $574.9M | $1.53B | $1.82B | $4.04B | $6.39B | $5.68B | $4.15B |
| Operating Income | -$223.8M | -$269.4M | -$468.9M | -$545.7M | -$763.1M | $13.30B | $9.42B | -$4.24B | -$3.94B | -$3.07B |
| EBITDA | -$208.7M | -$235.3M | -$412.1M | -$477.1M | -$703.4M | $13.54B | $9.95B | -$3.28B | -$3.39B | -$2.55B |
| Interest Expense | 0 | $132000 | $3.1M | $6.6M | $9.9M | $18.0M | $29.0M | $38.0M | $24.0M | $10.0M |
| Pre-tax Income | -$215.2M | -$256.0M | -$440.0M | -$514.7M | -$744.5M | $13.29B | $9.57B | -$3.94B | -$3.61B | -$2.77B |
| Income Tax | $1.0M | -$80000 | $326000 | -$695000 | $2.6M | $1.08B | $1.21B | $772.0M | -$46.0M | $54.0M |
| Net Income | -$216.2M | -$255.9M | -$384.7M | -$514.0M | -$747.1M | $12.20B | $8.36B | -$4.71B | -$3.56B | -$2.82B |
| EPS | $-3.79 | $-0.72 | $-1.17 | $-1.55 | $-1.96 | $30.31 | $21.26 | $-12.34 | $-9.27 | $-7.26 |
| EPS (Diluted) | $-3.79 | $-0.72 | $-1.17 | $-1.55 | $-1.96 | $28.29 | $20.10 | $-12.34 | $-9.27 | $-7.26 |
| Shares Outstanding (Diluted) | $64.1M | $376.0M | $328.8M | $330.8M | $381.3M | $431.0M | $416.0M | $382.0M | $384.0M | $389.0M |
Price
| Price | $155.16 |
| Market Cap | $61.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BBIO · BMRN · CAI · EXEL · HALO · JAZZ · MDGL
Explore sector: Healthcare · Biotechnology
More sections of MRNA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks